The -196°C Gambit: Resonant's Big Bet on Europe's Advanced Therapy Future

LEESBURG, VA – September 03, 2026 – In a move that sends a clear signal about the future of clinical trial logistics, Resonant Clinical Solutions announced today its acquisition of France-based Creapharm Bioservices. While corporate acquisitions are a daily feature of the business landscape, this particular transaction is less about simple consolidation and more about a strategic deep-freeze—a calculated play for dominance in the high-stakes, ultra-cold world of advanced therapy supply chains.

The deal sees Resonant, a global clinical solutions partner backed by Audax Private Equity, take control of the specialized biobanking and cryogenic storage firm from Myonex. On the surface, it's a straightforward expansion of Resonant's Biorepository capabilities in Europe. But dig deeper, and you find a story about infrastructure, expertise, and the quiet but frantic race to build the logistical backbone for the next generation of medicine. Financial terms were not disclosed, but the strategic value is crystal clear.

The Race for the Cold Chain

The pharmaceutical pipeline is undergoing a seismic shift. The era of the simple small-molecule pill is giving way to a new age of complex, living therapies. According to a 2025 IQVIA study, non-small-molecule assets—including cell and gene therapies, antibody-drug conjugates, and other advanced modalities—accounted for 46% of all Phase I–III clinical trial starts in 2024, a significant jump from 38% just five years earlier. The market for cell and gene therapies alone, valued at over $21 billion in 2024, is projected to explode to nearly $118 billion by 2034.

These are not treatments that can be stored on a warehouse shelf. They are highly sensitive, often patient-specific biological materials that require an unbroken, meticulously monitored "cold chain" at temperatures as low as -196°C (the temperature of vapor-phase liquid nitrogen). A minor fluctuation in temperature or a gap in the chain of custody can render a potentially life-saving, multi-million-dollar treatment inert and useless. This is where the battle for the future of clinical logistics is being fought—not in boardrooms, but in the sterile environments of cryogenic freezers.

Resonant's acquisition of Creapharm Bioservices is a direct insertion into the European front line of this battle. Creapharm isn't just another cold storage facility; it is a highly specialized operator with deep expertise in handling Advanced Therapy Medicinal Products (ATMPs), the regulatory term for these novel treatments. With its facility near Paris, Resonant gains more than just European real estate. It acquires a team with the technical know-how to manage everything from Class 2 genetically modified organisms (GMOs) to GMP/GDP-compliant storage, all under the watchful eye of European regulators like France's ANSM, which has authorized Creapharm for cell and tissue therapy storage.

This move sharpens Resonant's competitive edge against giants in the clinical supply space like Thermo Fisher Scientific, Catalent, and Marken. While these larger players offer broad cold chain solutions, the Creapharm acquisition provides Resonant with a focused, deeply specialized asset, positioning it as the go-to partner for biotech and pharma companies navigating the treacherous logistical waters of cell and gene therapy development in Europe.

Behind the Freezer Door: The Hidden Architecture of Modern Medicine

For those outside the industry, terms like "GMP-compliant infrastructure" and "ISO 20387 certification" can seem like impenetrable jargon. But for the scientists developing these therapies and the patients waiting for them, they are the bedrock of trust and safety. The Creapharm acquisition brings these critical capabilities into the Resonant fold, underscoring the hidden complexities of bringing modern medicine from the lab to the clinic.

"Life sciences companies increasingly need partners with the specialized expertise, infrastructure, and global reach to support more of the clinical trial lifecycle," said Christophe Berthoux, Chief Executive Officer, Resonant Clinical Solutions, in a statement accompanying the announcement. This acquisition, he noted, "strengthens our ability to support customers developing complex and sensitive therapies, including cell and gene therapies."

Creapharm’s capabilities are a case study in what this support entails. It’s about providing vapor-phase nitrogen storage that prevents cross-contamination. It’s about maintaining a flawless chain of custody, documented at every step, from the clinic where a patient's cells are harvested to the lab where they are modified, and back to the patient's bedside for infusion. It’s about having disaster recovery plans in place to protect irreplaceable biological assets from power outages or natural disasters. It’s about being the first private biobank in France to hold a trio of key certifications (ISO 9001, ISO 20387, NF S96-900), demonstrating a public commitment to the highest possible standards.

"Creapharm Bioservices strengthens the specialized support we can provide customers that are managing increasingly sensitive materials and complex clinical programs," added Corey Stone, Vice President and General Manager - Biorepository, Resonant Clinical Solutions. His excitement about welcoming the Creapharm team speaks to the value placed on human expertise in this technologically advanced field. The ability to handle these materials is as much an art as it is a science, requiring technical skill that is built over years.

A Strategic Divestment: Myonex's Calculated Pivot

Every acquisition has two sides, and the story from the seller, Myonex, is one of strategic focus. Interestingly, Myonex itself acquired Creapharm's broader operations—including clinical supply and packaging—as recently as March 2024. The decision to now divest the specialized Bioservices arm to Resonant less than three years later is a telling move. It reflects a deliberate, and likely shrewd, refinement of its corporate strategy.

In the press release, Myonex CEO Greg Lavin framed the transaction as a way to "further concentrate on our core strengths and future strategy." He described Creapharm Bioservices as a "natural fit for Resonant," a polite but clear acknowledgment that while the biobanking unit is valuable, its full potential could be better realized within a company whose core identity is more closely aligned with sample lifecycle management.

Myonex is a leader in its own right, with a strong market position in drug sourcing, clinical trial prescription services, and a growing business in packaging and labeling. By selling the highly specialized, capital-intensive biobanking unit, the company frees up resources and management focus to double down on these areas. This is not a retreat, but a strategic pivot. It’s an example of a company recognizing that in today's hyper-competitive clinical services market, trying to be everything to everyone is a losing proposition. True value is created by being the undisputed best in a well-defined domain.

The transaction allows Myonex to streamline its operations while ensuring the Creapharm Bioservices team and its clients land with a parent company dedicated to their specific niche. For Resonant, born from Audax Private Equity's 2024 carve-out of Avantor's clinical services business, this acquisition is another deliberate step in its mission to build a comprehensive, global powerhouse focused on the entire clinical supply chain and sample lifecycle. The addition of Creapharm's deep cryogenic expertise is not just an expansion; it's a declaration of intent in one of the most critical and fastest-growing sectors of modern healthcare.